Core Viewpoint - The inclusion of the drug Praluent® (Pralsetinib capsules, 100 mg) in China's National Medical Insurance Catalog is a significant development for the company, as it will officially take effect on January 1, 2026, enhancing the drug's market access and potential sales in the region [1]. Group 1: Drug Approval and Indications - Praluent® is an oral targeted therapy approved by the National Medical Products Administration (NMPA) for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are RET gene fusion positive, as well as for adult and pediatric patients aged 12 and above with advanced or metastatic RET mutation medullary thyroid carcinoma (MTC) requiring systemic treatment [1][2]. - The drug has also been approved in Hong Kong for treating adult patients with metastatic RET fusion-positive NSCLC and in Taiwan for similar indications, including advanced or metastatic RET fusion-positive thyroid cancer [1]. Group 2: Commercialization and Partnerships - The drug Praluent® was developed by Blueprint Medicines, which was acquired by Sanofi in July 2025, indicating a strategic partnership that may enhance the drug's development and commercialization efforts [2]. - The company has granted exclusive commercialization rights for Praluent® in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd. as of November 2023, which may streamline marketing and distribution efforts in the region [2].